A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain
Primary Purpose: Treatment
Number of participants with adverse events using the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 4 as a measure of safety and tolerability in subjects with chronic pain refractory to opioid therapy.
Patients will be followed weekly for 8 weeks, then monthly for up to 6 months.
United States: Food and Drug Administration
|University of Texas Southwestern Medical Center||Dallas, Texas|